PDF(Pubmed)
Abstract：
UNASSIGNED: During percutaneous transluminal coronary angioplasty (PTCA), activated clotting time (ACT) measurements are recommended to attest a correct anticoagulation level and, if needed, to administer further unfractionated heparin (UFH) to obtain a therapeutic ACT value. Our clinical routine led us to observe that smokers had lower ACT values after standardized UFH administration during PTCA. Procoagulant status in smokers is well documented.
UNASSIGNED: To determine whether tobacco negatively affects UFH anticoagulation during PTCA when evaluated by ACT.
UNASSIGNED: The ACT-TOBACCO trial is a single-center, noninterventional, prospective study. The primary end point is the comparison of ACT values after standardized UFH administration between active smokers and nonsmokers (active smoker group vs nonsmoker group) requiring coronary angiography followed by PTCA. The main secondary end points include ACT comparison after the first and second standardized UFH administration according to the patient\'s smoking status (active, ex-, or nonsmoker) and the clinical presentation of ischemic cardiomyopathy: stable (silent ischemia or stable angina) or unstable (unstable angina or acute coronary syndrome without or with ST-segment elevation).
UNASSIGNED: To the best of our knowledge, ACT values during PTCA between smokers and nonsmokers have not previously been compared. As current PTCA procedures increase in complexity and duration, the understanding of procoagulant risk factors such as smoking and the need for reliable anticoagulation monitoring becomes essential to balance hemorrhagic risk against thrombotic risk.
UNASSIGNED: To determine whether tobacco negatively affects UFH anticoagulation during PTCA when evaluated by ACT.
UNASSIGNED: The ACT-TOBACCO trial is a single-center, noninterventional, prospective study. The primary end point is the comparison of ACT values after standardized UFH administration between active smokers and nonsmokers (active smoker group vs nonsmoker group) requiring coronary angiography followed by PTCA. The main secondary end points include ACT comparison after the first and second standardized UFH administration according to the patient\'s smoking status (active, ex-, or nonsmoker) and the clinical presentation of ischemic cardiomyopathy: stable (silent ischemia or stable angina) or unstable (unstable angina or acute coronary syndrome without or with ST-segment elevation).
UNASSIGNED: To the best of our knowledge, ACT values during PTCA between smokers and nonsmokers have not previously been compared. As current PTCA procedures increase in complexity and duration, the understanding of procoagulant risk factors such as smoking and the need for reliable anticoagulation monitoring becomes essential to balance hemorrhagic risk against thrombotic risk.
摘要：
未经证实：经皮冠状动脉腔内成形术（PTCA）期间，建议测量激活凝血时间（ACT）以证明正确的抗凝水平，如果需要,给予进一步的普通肝素(UFH)以获得治疗性ACT值。我们的临床常规使我们观察到，在PTCA期间，标准化UFH给药后，吸烟者的ACT值较低。吸烟者的促凝血状态是有据可查的。
UNASSIGNED：当通过ACT评估时，确定烟草是否会对PTCA期间的UFH抗凝产生负面影响。
未经批准：ACT-TOBACCO试验是单中心，非干预性，前瞻性研究。主要终点是主动吸烟者和非吸烟者（主动吸烟者组与非吸烟者组）之间标准化UFH给药后需要冠状动脉造影和PTCA的ACT值的比较。主要的次要终点包括根据患者的吸烟状况（活跃，ex-,或不吸烟者）和缺血性心肌病的临床表现：稳定（无症状缺血或稳定型心绞痛）或不稳定（不稳定型心绞痛或急性冠状动脉综合征，无或伴有ST段抬高）。
未经授权：据我们所知，以前没有比较吸烟者和非吸烟者在PTCA期间的ACT值。随着当前PTCA程序的复杂性和持续时间的增加，对吸烟等促凝危险因素的了解以及可靠抗凝监测的必要性对于平衡出血风险和血栓风险至关重要.
UNASSIGNED：当通过ACT评估时，确定烟草是否会对PTCA期间的UFH抗凝产生负面影响。
未经批准：ACT-TOBACCO试验是单中心，非干预性，前瞻性研究。主要终点是主动吸烟者和非吸烟者（主动吸烟者组与非吸烟者组）之间标准化UFH给药后需要冠状动脉造影和PTCA的ACT值的比较。主要的次要终点包括根据患者的吸烟状况（活跃，ex-,或不吸烟者）和缺血性心肌病的临床表现：稳定（无症状缺血或稳定型心绞痛）或不稳定（不稳定型心绞痛或急性冠状动脉综合征，无或伴有ST段抬高）。
未经授权：据我们所知，以前没有比较吸烟者和非吸烟者在PTCA期间的ACT值。随着当前PTCA程序的复杂性和持续时间的增加，对吸烟等促凝危险因素的了解以及可靠抗凝监测的必要性对于平衡出血风险和血栓风险至关重要.
